Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis

Experimental and Molecular Pathology

Volumn 93, Issue 1, 2012, Pages 26-34

  Oliva, Joan ^a   French, Samuel W ^a   Li, Jun ^a   Bardag Gorce, Fawzia ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Fatty acid; Proteasome inhibitor; Triacylglycerol and cholesterol synthesis

Indexed keywords

ACETYL COENZYME A; ACETYL COENZYME A CARBOXYLASE; ALCOHOL; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1 COMPLEMENTATION FACTOR; APOLIPOPROTEIN C3; BORTEZOMIB; CCAAT ENHANCER BINDING PROTEIN ALPHA; CHOLESTEROL; DIACYLGLYCEROL ACYLTRANSFERASE; FATTY ACID; FATTY ACID SYNTHASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; LIPOPROTEIN LIPASE; LIPOPROTEIN RECEPTOR; MALONYL COENZYME A; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADSORPTION; ALCOHOL CONSUMPTION; ALCOHOLIC FATTY LIVER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FATTY ACID SYNTHESIS; GENE EXPRESSION; LIPOGENESIS; LIVER; MALE; MICROARRAY ANALYSIS; MORPHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ALCOHOL DRINKING; ANIMALS; ANTINEOPLASTIC AGENTS; APOLIPOPROTEINS; BORONIC ACIDS; CHOLESTEROL; DOWN-REGULATION; FATTY ACIDS; FATTY LIVER, ALCOHOLIC; INTESTINAL ABSORPTION; LIPID METABOLISM; MALE; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RATS; RATS, WISTAR; TRIGLYCERIDES;

ANIMALIA; RATTUS;

EID: 84860810068     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.03.006     Document Type: Article

References (45)

1. Agarwal A.K., Garg A. Enzymatic activity of the human 1-acylglycerol-3-phosphate-O-acyltransferase isoform 11: upregulated in breast and cervical cancers. Journal of Lipid Research 2010, 51(8):2143-2152. Epub 2010 Apr 2.
2. Ajmo J.M., Liang X., Rogers C.Q., Pennock B., You M. Resveratrol alleviates alcoholic fatty liver in mice. American Journal of Physiology. Gastrointestinal and Liver Physiology 2008, 295(4):G833-G842.
3. Bardag-Gorce F., French B.A., Li J., Riley N.E., Yuan Q.X., Valinluck V., Fu P., Ingelman-Sundberg M., Yoon S., French S.W. The importance of cycling of blood alcohol levels in the pathogenesis of experimental alcoholic liver disease in rats. Gastroenterology 2002, 123(1):325-335.
4. Bardag-Gorce F., Vu J., Nan L., Riley N., Li J., French S.W. Proteasome inhibition induces cytokeratin accumulation in vivo. Experimental and Molecular Pathology 2004, 76(2):83-89.
5. Bardag-Gorce F., French B.A., Dedes J., Li J., French S.W. Gene expression patterns of the liver in response to alcohol: in vivo and in vitro models compared. Experimental and Molecular Pathology 2006, 80:241-251.
6. Bardag-Gorce F., Li J., Oliva J., Lu S.C., French B.A., French S.W. The cyclic pattern of blood alcohol levels during continuous ethanol feeding in rats: the effect of feeding S-adenosylmethionine. Experimental and Molecular Pathology 2010, 88(3):380-387.
7. Bardag-Gorce F., Oliva J., Wong W., Fong S., Li J., French B.A., French S.W. S-adenosylmethionine decreases the peak blood alcohol levels 3 h after an acute bolus of ethanol by inducing alcohol metabolizing enzymes in the liver. Experimental and Molecular Pathology 2010, 89(3):217-221.
8. Bardag-Gorce F., Oliva J., Lin A., Li J., French B.A., French S.W. Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease. Experimental and Molecular Pathology 2011, 90(1):123-130. (Epub 2010 Oct 29, PMID: 21036165).
9. Bergheim I., Guo L., Davis M.A., Lambert J.C., Beier J.I., Duveau I., Luyendyk J.P., Roth R.A., Arteel G.E. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006, 130(7):2099-2112.
10. Bold R. "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D. Cancer Investigation 2004, 22(2):328-329.
11. Carrasco M.P., Marco C., Segovia J.L. Chronic ingestion of ethanol stimulates lipogenic response in rat hepatocytes. Life Sciences 2001, 68:1295-1304.
12. Carrasco M.P., Jimenez-Lopez J.M., Segovia J.L., Marco C. Comparative study of the effects of short- and long-term ethanol treatment and alcohol withdrawal on phospholipid biosynthesis in rat hepatocytes. Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology 2002, 131:491-497.
13. Chen D., Cui Q.C., Yang H., Dou Q.P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Research 2006, 66(21):10425-10433.
14. Chen X., Sebastian B.M., Tang H., McMullen M.M., Axhemi A., Jacobsen D.W., Nagy L.E. Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats. Hepatology 2009, 49(5):1554-1562.
15. Crabb D.W., Liangpunsakul S. Alcohol and lipid metabolism. Journal of Gastroenterology and Hepatology 2006, 21(Suppl. 3):S56-S60.
16. Cvek B., Dvorak Z. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?. Drug Discovery Today 2008, 13(15-16):716-722.
17. French S.W. Intragastric ethanol infusion model for cellular and molecular studies of alcoholic liver disease. Journal of Biomedical Science 2001, 8:20-27.
18. Greenberg A.S., Nordan R.P., McIntosh J., Calvo J.C., Scow R.O., Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Research 1992, 52(15):4113-4116.
19. Ji C., Chan C., Kaplowitz N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. Journal of Hepatology 2006, 45(5):717-724.
20. Kaplowitz N., Ji C. Unfolding new mechanisms of alcoholic liver disease in the endoplasmic reticulum. Journal of Gastroenterology and Hepatology 2006, 21(Suppl. 3):S7-S9.
21. Kharbanda K.K. Alcoholic liver disease and methionine metabolism. Seminars in Liver Disease 2009, 29(2):155-165.
22. Kim Y.W., Kim Y.M., Yang Y.M., Kim T.H., Hwang S.J., Lee J.R., Kim S.C., Kim S.G. Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis. Free Radical Biology & Medicine 2010, 48(4):567-578.
23. Lucey M.R. Management of alcoholic liver disease. Clinics in Liver Disease 2009, 13(2):267-275.
24. Ludwig A., Friedel B., Metzkow S., Meiners S., Stangl V., Baumann G., Stangl K. Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. Biochemical Pharmacology 2005, 15;70(4):520-526.
25. Mato J.M., Cámara J., Fernández de Paz J., Caballería L., Coll S., Caballero A., García-Buey L., Beltrán J., Benita V., Caballería J., Solà R., Moreno-Otero R., Barrao F., Martín-Duce A., Correa J.A., Parés A., Barrao E., García-Magaz I., Puerta J.L., Moreno J., Boissard G., Ortiz P., Rodés J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology 1999, 30(6):1081-1089.
26. Matsuda D., Tomoda H. DGAT inhibitors for obesity. Current Opinion in Investigational Drugs 2007, 8(10):836-841.
27. Matsuda D., Tomoda H. Triazolo compounds useful as diacylglycerol acyltransferase1 inhibitor - WO2009126624. Expert Opinion on Therapeutic Patents 2010, 20(8):1097-1102.
28. Mutschler J., Diehl A., Vollmert C., Herre H., Mann K., Kiefer F. Recent results in relapse prevention of alcoholism with Disulfiram. Neuropsychiatry 2008, 22(4):243-251.
29. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Dunner K., Huang P., Abbruzzese J.L., McConkey D.J. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Research 2005, 65(24):11658-11666.
30. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107(12):4907-4916.
31. Oliva J., Dedes J., Li J., French S.W., Bardag-Gorce F. Epigenetics of proteasome inhibition in the liver of rats fed ethanol chronically. World Journal of Gastroenterology 2009, 15(6):705-712.
32. Payne V.A., Au W.S., Lowe C.E., Rahman S.M., Friedman J.E., O'Rahilly S., Rochford J.J. C/EBP transcription factors regulate SREBP1c gene expression during adipogenesis. The Biochemical Journal 2009, 425(1):215-223.
33. Purohit V., Abdelmalek M.F., Barve S., Benevenga N.J., Halsted C.H., Kaplowitz N., Kharbanda K.K., Liu Q.Y., Lu S.C., McClain C.J., Swanson C., Zakhari S. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. The American Journal of Clinical Nutrition 2007, 86(1):14-24.
34. Rickardson L., Wickström M., Larsson R., Lövborg H. Image-based screening for the identification of novel proteasome inhibitors. Journal of Biomolecular Screening 2007, 12(2):203-210.
35. Ruixing Y., Yiyang L., Meng L., Kela L., Xingjiang L., Lin Z., Wanying L., Jinzhen W., Dezhai Y., Weixiong L. Interactions of the apolipoprotein C-III 3238C>G polymorphism and alcohol consumption on serum triglyceride levels. Lipids in Health and Disease 2010, 17(9):86.
36. Rutledge A.C., Qiu W., Zhang R., Kohen-Avramoglu R., Nemat-Gorgani N., Adeli K. Mechanisms targeting apolipoprotein B100 to proteasomal degradation: evidence that degradation is initiated by BiP binding at the N terminus and the formation of a p97 complex at the C terminus. Arteriosclerosis, Thrombosis, and Vascular Biology 2009, 29(4):579-585. Epub 2009 Jan 22.
37. Rzymski T., Milani M., Singleton D.C., Harris A.L. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 2009, 8(23):3838-3847.
38. Sanal M.G. The blind men 'see' the elephant-the many faces of fatty liver disease. World Journal of Gastroenterology 2008, 14(6):831-844.
39. Shimano H., Horton J.D., Hammer R.E., Shimomura I., Brown M.S., Goldstein J.L. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. The Journal of Clinical Investigation 1996, 98:1575-1584.
40. Tomita K., Azuma T., Kitamura N., Nishida J., Tamiya G., Oka A., Inokuchi S., Nishimura T., Suematsu M., Ishii H. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 2004, 126(3):873-885.
41. Tsukamoto H., Matsuoka M., French S.W. Experimental models of hepatic fibrosis: a review. Seminars in Liver Disease 1990, 10(1):56-65. Review.
42. Yamamoto T., Yamaguchi H., Miki H., Kitamura S., Nakada Y., Aicher T.D., Pratt S.A., Kato K. A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity. European Journal of Pharmacology 2011, 650(2-3):663-672. Epub 2010 Oct 29.
43. You M., Crabb D.W. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol 2004, 34:39-43.
44. You M., Fischer M., Deeg M.A., Crabb D.W. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). The Journal of Biological Chemistry 2002, 277:29342-29347.
45. You M., Matsumoto M., Pacold C.M., Cho W.K., Crabb D.W. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 2004, 127:1798-1808.